Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker MRNA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Study of Updated mRNA Seasonal Influenza Vaccines NCT07884175 · Seasonal Influenza mRNA-1010, Licensed High-Dose Seasonal Influenza Vaccine | MRNA ModernaTX, Inc. | Phase 4 | Recruiting was not yet recruiting | 200 | Dec 7, 2026 | Registry ↗ |
| Nov 9, 2026 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6… NCT07808697 · SARS-CoV-2 mRNA-1283, mRNA-1273 | MRNA ModernaTX, Inc. | Phase 2 | Recruiting was not yet recruiting | 300 | Aug 30, 2029 | Registry ↗ |
| Nov 5, 2026 | A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of a Preventative Vaccine for… NCT07919210 · Marburg Virus Disease (MVD) mRNA-1519, Placebo | MRNA ModernaTX, Inc. | Phase 1 | Not yet recruiting | 64 | Apr 14, 2028 | Registry ↗ |
| Nov 5, 2026 | A Study to Investigate the Safety and Immunogenicity of mRNA-1469 in African Participants 1 to 65 Y… NCT07919197 · Ebola-Bundibugyo Virus Disease (Ebola-BDBV) mRNA-1469, Placebo | MRNA ModernaTX, Inc. | Phase 1 | Not yet recruiting | 224 | Feb 1, 2028 | Registry ↗ |
| Nov 5, 2026 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children NCT07870330 · Seasonal Influenza mRNA-1010, Fluarix Trivalent | MRNA ModernaTX, Inc. | Phase 1 | Recruiting | 96 | Dec 7, 2027 | Registry ↗ |
| Nov 4, 2026 | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulatio… NCT07863635 · SARS-CoV-2 mRNA-1273, mRNA-1283 | MRNA ModernaTX, Inc. | Phase 4 | Recruiting | 600 | Dec 11, 2026 | Registry ↗ |
| Nov 4, 2026 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy… NCT05831111 · Epstein-Barr Virus Infection mRNA-1195.1, mRNA-1195.2 | MRNA ModernaTX, Inc. | Phase 1 | Completed was active, not recruiting | 482 | Oct 14, 2026 | Registry ↗ |
| Oct 23, 2026 | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prev… NCT05992935 · Norovirus Acute Gastroenteritis mRNA-1403, mRNA-1405 | MRNA ModernaTX, Inc. | Phase 1/2 | Completed | 1,407 | Oct 7, 2026 | Registry ↗ |
| Oct 13, 2026 | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in P… NCT06880549 · Advanced Solid Tumors mRNA-4106, Pembrolizumab | MRNA ModernaTX, Inc. | Phase 1 | Recruiting | 42 | Aug 3, 2027 | Registry ↗ |
| Oct 8, 2026 | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of… NCT06508320 · Influenza, SARS-CoV-2 mRNA-1083 | MRNA ModernaTX, Inc. | Phase 2 | Completed | 931 | Sep 25, 2025 | Registry ↗ |
| Sep 29, 2026 | A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Vi… NCT05127434 · Respiratory Syncytial Virus Placebo, mRNA-1345 | MRNA ModernaTX, Inc. | Phase 2/3 | Completed | 36,814 | Jul 28, 2025 | Registry ↗ |
| Sep 28, 2026 | A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Yea… NCT07266558 · SARS-CoV-2 mRNA-1273, mRNA-1283 | MRNA ModernaTX, Inc. | Phase 4 | Active, not recruiting | 30,000 | Jun 16, 2027 | Registry ↗ |
| Sep 24, 2026 | A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Preve… NCT07737717 · Ebola-Bundibugyo Virus Disease (Ebola-BDBV) mRNA-1469, Placebo | MRNA ModernaTX, Inc. | Phase 1 | Active, not recruiting | 84 | Sep 30, 2027 | Registry ↗ |
| Sep 23, 2026 | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma NCT07116616 · Relapsed or Refractory Multiple Myeloma mRNA-2808 | MRNA ModernaTX, Inc. | Phase 1/2 | Recruiting | 190 | Jun 17, 2030 | Registry ↗ |
| Sep 16, 2026 | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age NCT06602024 · Seasonal Influenza mRNA-1010, Fluarix® | MRNA ModernaTX, Inc. | Phase 3 | Completed | 40,805 | Aug 21, 2025 | Registry ↗ |
| Sep 15, 2026 | A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy… NCT06655870 · Healthy Participants mRNA-0184 | MRNA ModernaTX, Inc. | Phase 1 | Recruiting | 42 | Dec 16, 2026 | Registry ↗ |
| Sep 8, 2026 | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembroli… NCT03897881 · Melanoma mRNA-4157, Pembrolizumab | MRNA ModernaTX, Inc. | Phase 2 | Active, not recruiting | 267 | Nov 21, 2032 | Registry ↗ |
| Sep 3, 2026 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With… NCT03313778 · Solid Tumors mRNA-4157, Pembrolizumab | MRNA ModernaTX, Inc. | Phase 1 | Active, not recruiting | 161 | Nov 21, 2027 | Registry ↗ |
| Aug 20, 2026 | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syn… NCT06067230 · Respiratory Syncytial Virus mRNA-1345 | MRNA ModernaTX, Inc. | Phase 3 | Completed | 1,153 | Jul 24, 2026 | Registry ↗ |
| Aug 19, 2026 | A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older… NCT07764237 · Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (… mRNA-1365 (Profile 2), mRNA-1345 (Profile 1) | MRNA ModernaTX, Inc. | Phase 1 | Recruiting | 375 | Jul 20, 2027 | Registry ↗ |
| Aug 18, 2026 | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Y… NCT06097299 · Respiratory Syncytial Virus mRNA-1345, Placebo | MRNA ModernaTX, Inc. | Phase 2 | Completed | 349 | Jun 27, 2025 | Registry ↗ |
| Aug 11, 2026 | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults NCT07496450 · Influenza mRNA-1018-H5, Placebo | MRNA ModernaTX, Inc. | Phase 3 | Active, not recruiting | 4,050 | Jan 28, 2027 | Registry ↗ |
| Aug 10, 2026 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vac… NCT05683457 · Cytomegalovirus Infection mRNA-1647, Placebo | MRNA ModernaTX, Inc. | Phase 2 | Active, not recruiting | 84 | Mar 6, 2027 | Registry ↗ |
| Aug 5, 2026 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥… NCT05701800 · Herpes Zoster mRNA-1468, Placebo | MRNA ModernaTX, Inc. | Phase 1 | Terminated | 659 | Dec 31, 2025 | Registry ↗ |
| Aug 3, 2026 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Dis… NCT07561294 · Lyme Disease mRNA-1982, Placebo | MRNA ModernaTX, Inc. | Phase 2 | Active, not recruiting | 366 | Nov 9, 2028 | Registry ↗ |
| Jul 30, 2026 | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease i… NCT05975099 · Lyme Disease mRNA-1975, mRNA-1982 | MRNA ModernaTX, Inc. | Phase 1/2 | Completed | 807 | May 30, 2025 | Registry ↗ |
| Jul 14, 2026 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Partici… NCT05533697 · Advanced Solid Tumors mRNA-4359, Pembrolizumab | MRNA ModernaTX, Inc. | Phase 1/2 | Recruiting | 361 | Feb 18, 2032 | Registry ↗ |
| Jul 7, 2026 | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulat… NCT07089706 · COVID-19 mRNA-1283.251 Variant-containing Formulation | MRNA ModernaTX, Inc. | Phase 4 | Completed | 832 | Jun 16, 2026 | Registry ↗ |
| Jun 26, 2026 | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5… NCT05743881 · Respiratory Syncytial Virus, Human Metapneumovirus mRNA-1345, mRNA-1365 | MRNA ModernaTX, Inc. | Phase 1 | Active, not recruiting | 186 | Aug 31, 2029 | Registry ↗ |
| Jun 15, 2026 | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo i… NCT06735248 · Multiple Sclerosis mRNA-1195, Placebo | MRNA ModernaTX, Inc. | Phase 2 | Recruiting | 180 | Jan 8, 2029 | Registry ↗ |
| Jun 10, 2026 | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants… NCT06143046 · Respiratory Syncytial Virus mRNA-1345, Placebo | MRNA ModernaTX, Inc. | Phase 2 | Completed | 360 | May 25, 2026 | Registry ↗ |
| Jun 4, 2026 | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Parti… NCT05575492 · Cytomegalovirus mRNA-1647, Placebo | MRNA ModernaTX, Inc. | Phase 1/2 | Completed | 873 | May 12, 2026 | Registry ↗ |
| May 13, 2026 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for th… NCT06592794 · Acute Gastroenteritis, Norovirus Acute Gastroenteritis mRNA-1403, Placebo | MRNA ModernaTX, Inc. | Phase 3 | Active, not recruiting | 37,864 | Feb 15, 2027 | Registry ↗ |
| May 8, 2026 | A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy A… NCT06033261 · Genital Herpes mRNA-1608, BEXSERO | MRNA ModernaTX, Inc. | Phase 1/2 | Completed | 303 | Apr 25, 2025 | Registry ↗ |
| May 6, 2026 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy… NCT05164094 · Epstein-Barr Virus Infection mRNA-1189, Placebo | MRNA ModernaTX, Inc. | Phase 1/2 | Active, not recruiting | 867 | Oct 5, 2026 | Registry ↗ |
| May 6, 2026 | A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants W… NCT04899310 · Methylmalonic Acidemia mRNA-3705, Placebo | MRNA ModernaTX, Inc. | Phase 1/2 | Terminated | 18 | Apr 1, 2026 | Registry ↗ |
| May 5, 2026 | Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-… NCT04232280 · Cytomegalovirus Infection mRNA-1647, Placebo | MRNA ModernaTX, Inc. | Phase 2 | Completed | 315 | Jan 4, 2023 | Registry ↗ |
| May 4, 2026 | A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial V… NCT07117487 · Respiratory Syncytial Virus mRNA-1345 | MRNA ModernaTX, Inc. | Phase 3 | Completed | 507 | Mar 27, 2026 | Registry ↗ |
| May 1, 2026 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age t… NCT05815498 · COVID-19 mRNA-1283.222, mRNA-1273.222 | MRNA ModernaTX, Inc. | Phase 3 | Completed | 13,553 | Apr 12, 2025 | Registry ↗ |
| Apr 16, 2026 | Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Inject… NCT06333704 · SARS-CoV-2 SPIKEVAX Bivalent BA.1, SPIKEVAX Bivalent BA.4/5 | MRNA ModernaTX, Inc. | — | Active, not recruiting | 4,207 | Mar 29, 2029 | Registry ↗ |
| Mar 27, 2026 | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Fo… NCT06585241 · SARS-CoV-2 mRNA-1273 Variant-containing Formulation | MRNA ModernaTX, Inc. | Phase 4 | Recruiting | 1,144 | Dec 31, 2026 | Registry ↗ |
| Mar 24, 2026 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Year… NCT07478952 · Epstein-Barr Virus mRNA-1189 | MRNA ModernaTX, Inc. | Phase 1 | Recruiting | 120 | May 15, 2027 | Registry ↗ |
| Mar 23, 2026 | A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previousl… NCT05130437 · Propionic Acidemia mRNA-3927 | MRNA ModernaTX, Inc. | Phase 1/2 | Recruiting | 50 | Dec 4, 2029 | Registry ↗ |
| Mar 12, 2026 | A Study of Modified mRNA Vaccines in Healthy Adults NCT05397223 · SARS-CoV-2, Seasonal Influenza mRNA-1273, mRNA-1010 | MRNA ModernaTX, Inc. | Phase 1 | Completed | 308 | Feb 27, 2026 | Registry ↗ |
| Feb 5, 2026 | A Retrospective Study to Characterize Participants With Propionic Acidemia NCT05769621 · Propionic Acidemia | MRNA ModernaTX, Inc. | — | Recruiting | 60 | Sep 30, 2026 | Registry ↗ |
| Feb 4, 2026 | A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Throu… NCT06634797 · Healthy Volunteers mRNA-1273.712, Placebo | MRNA ModernaTX, Inc. | Phase 4 | Completed | 1,000 | Jan 20, 2025 | Registry ↗ |
| Feb 2, 2026 | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA… NCT04975893 · Cytomegalovirus Infection mRNA-1647, mRNA-1647 | MRNA ModernaTX, Inc. | Phase 2 | Completed | 135 | Jan 19, 2026 | Registry ↗ |
| Jan 22, 2026 | Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia NCT04159103 · Propionic Acidemia mRNA-3927 | MRNA ModernaTX, Inc. | Phase 1/2 | Recruiting | 77 | Aug 31, 2027 | Registry ↗ |
| Dec 30, 2025 | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age NCT05330975 · Respiratory Syncytial Virus Placebo, mRNA-1345 | MRNA ModernaTX, Inc. | Phase 3 | Completed | 3,317 | Nov 8, 2024 | Registry ↗ |
| Dec 23, 2025 | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults NCT05827926 · SARS-CoV-2, Influenza Influenza Vaccine 1, mRNA-1083.1 | MRNA ModernaTX, Inc. | Phase 1/2 | Completed | 1,758 | Dec 3, 2024 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 10:10 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances